alexa Effect Of Heart Failure Reversal Treatment As Add-on Therapy In Patients With Chronic Heart Failure: A Randomized, Open-label Study
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

World Heart Congress
May 22- 24, 2017 Osaka, Japan

Rohit Sane and Rahul Mandole
Madhavbaug Institute of Preventive Cardiology, India
Posters & Accepted Abstracts: J Clin Exp Cardiolog
DOI: 10.4172/2155-9880-C1-069
Objectives: Present study was designed to evaluate the effect of heart failure reversal therapy (HFRT) using herbal procedure (Panchakarma) and allied therapies, as add-on to standard CHF treatment (SCT) in chronic heart failure (CHF) patients. Methods: This open-label, randomized study conducted in CHF patients (aged: 25-65 years, ejection fraction: 30-65%), had 3-phases: 1-week screening, 6-week treatment (randomized [1:1] to HFRT + SCT or SCT-alone) and follow-up (12-week). Twice weekly HFRT (60-75 min) consisting of snehana (external oleation), swedana (passive heat therapy), hrudaydhara (concoction dripping treatment) and basti (enema) was administered. Primary endpoints included evaluation of change in metabolic equivalents of task (MET) and peak oxygen uptake (VO2peak) from baseline, at the end of the 6-week treatment and follow-up at week-18 (non-parametric rank ANCOVA analysis), safety and quality of life (QoL) was assessed. Results: 70 CHF patients (n=35, each treatment-arm; mean [SD] age: 53.0 [8.6], 80% men) were enrolled in the study. All patients completed treatment phase. Add-on HFRT caused a significant increase in METs (least square mean difference [LSMD], 6-week: 1.536, p=0.0002; 18-week: 1.254, p=0.0089) and VO2peak (LSMD, 6-week: 5.52, p=0.0002; 18-week: 4.517, p=0.0089) as compared with SCT alone. Results suggested improved functional capacity in patients with HFRT (QoL; Mean [SD] HFRT+SCT vs. SCT-alone; 6-week: 0.44 [0.34] vs. 0.06 [0.25], p<0.0001 and 18-week: 0.53 [0.35] vs. 0.29 [0.26], p=0.0013). Seven treatment-emergent adverse events (mild severity) were reported in HFRT-arm. Conclusion: Findings of this study highlight therapeutic efficacy of add-on HFRT vs. SCT-alone in CHF patients. The non-invasive HFRT showed no safety concerns.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version